RGRX (Regenerx Biopharmaceuticals) Total Inventories: $0.00 Mil (As of Mar. 2023)


What is Regenerx Biopharmaceuticals Total Inventories?

Regenerx Biopharmaceuticals RGRX Total Inventories is $0.00 Mil as of Mar. 2023.

Regenerx Biopharmaceuticals's total inventories for the quarter that ended in Mar. 2023 was $0.00 Mil. Regenerx Biopharmaceuticals's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Mar. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Regenerx Biopharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2023 was $-2.67.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Regenerx Biopharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2023 was 0.00.

Regenerx Biopharmaceuticals  (OTCPK:RGRX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Regenerx Biopharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2023 is

Net-Net Working Capital Per Share (Q: Mar. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.102+0.75 * 0+0.5 * 0-3.931
-0-0)/1.435
=-2.67

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Regenerx Biopharmaceuticals's Days Inventory for the three months ended in Mar. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2023 )/Cost of Goods Sold (Q: Mar. 2023 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Regenerx Biopharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2023 ) / Average Total Inventories (Q: Mar. 2023 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Regenerx Biopharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=0 / 0.019
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Regenerx Biopharmaceuticals Total Inventories Related Terms

Regenerx Biopharmaceuticals Total Inventories Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Total Inventories Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenerx Biopharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Total Inventories of $0.00 Mil as of Mar. 2023. The total amount of inventory as recorded on a company's balance sheet. View historical data for Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Total Inventories too high?
Regenerx Biopharmaceuticals' current Total Inventories is $0.00 Mil.
How does Regenerx Biopharmaceuticals' Total Inventories compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Total Inventories is $0.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.